EraGen Biosciences, Inc. company is developing nucleic databases and other tools to help drug and diagnostics developers better use genomic information to streamline their R&D processes. Molecular clinical diagnostics, bioterrorism threat detection, and pesonalized medicine are other markets the company is pursuing. EraGen Biosciences has teamed with Luminex to distribute in vitro clinical diagnostics equipment that uses technology from both companies. Bayer HealthCare has licensed the company's MultiCode-PLx test for detecting cystic fibrosis.

Solvay Pharmaceuticals is out to solve the medical maladies of the world. Part of Solvay SA's pharmaceuticals division, the US-based company develops, produces, and markets therapies for cardiovascular, gastroenterological, and neurological disorders. Solvay Pharmaceuticals also makes and markets flu vaccines and products for specialized markets such as women's and men's health. Its marketed products include AndroGel (testosterone replacement gel), Marinol (appetite stimulator and antiemetic), and ACEON (an antihypertension drug). Abbott Laboratories has agreed to acquire the Solvay Pharmaceuticals organization. Solvay Pharmaceuticals is led by CEO Stephen Hill.

Laboratoires Arkopharma's products offer a glimpse of modern worries: ampoules of fat reducers, tablets to help quit smoking, creams to tackle cellulite, and capsules to alleviate anxiety and stress. Arkopharma produces plant-derived OTC drugs and nutritional supplements. The company also manufactures homeopathic remedies and cosmetics. Arkopharma markets its products under a variety of brands, including Arkocaps, Arkofluide, 4.3.2.1. Slim, Phyto Soya, and Plante System. Subsidiaries of the company can be found in Australia, Europe, and the UK. The founding Rombi family controls the company through its holding company Imarko.

DPT Laboratories will turn a discovered drug into a developed and commercialized drug. The contract manufacturing and development company makes prescription and over-the-counter drugs with an emphasis on semi-solid and liquid formulations including lotions, gels, aerosol foams, nasal sprays, and creams. It works with both conventional and biopharmaceutical compounds and can manufacture small quantities for pilots and clinical trials, and all the way up to commercial production. DPT is a subsidiary of DFB Pharmaceuticals and has manufacturing facilities in Texas and New Jersey.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Santarus was founded in 1996 and is based in San Diego, California. Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of traveler’s diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

Corcept Therapeutics Incorporated company was founded in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.